A genetically engineered single-gene-encoded anti-TAG72 chimeric antibody secreted from myeloma cells
1Saskatoon Cancer Center, Department of Microbiology, University of Saskatchewan, Canada.
Abstract:
SP2/0Ag14 murine myeloma cells transfected with the expression vector mpSV2neo-EP-FV-CH2-3-PA containing the single gene FV-CH2-3 secreted a single-gene-encoded chimeric antibody molecule FV/M4. This single-chain protein consisted of the heavy- and light-chain variable (VH and VL) domains covalently joined through a flexible linker peptide, while the carboxyl end of VL domain was connected to the amino terminus of hinge region of the ccM4 heavy-chain. Our data showed that the FV/M4 retained both its immunoreactivity for tumor-associated TAG72 antigen and its cytolytic activity to tumor cells as did the parental ccM4 antibody. Therefore, this single-gene-construct approach circumvents inefficiencies inherent in delivering two genes into a mammalian cell for assembly of a functional chimeric antibody and provides an alternative for construction of chimeric antibodies. It is particularly attractive for ex vivo transfection of cells from patients for certain gene-therapy modalities not only for cancer but also for a range of diseases in which immunotherapeutic approaches are used.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Tagging and Fusion Proteins
Antiprotozoal Agents


